PDL BioPharma (PDLI) Posts Q1 EPS of $0.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- Wall St set for higher open as soft inflation data eases rate-hike fears
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil gains as stalled US-Iran talks trump supply recovery
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- HPE raises networking revenue outlook, secures $1.2B Vultr order
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
PDL BioPharma Announces First Quarter 2017 Financial Results
May 3, 2017 4:02 PM EDTINCLINE VILLAGE, Nev., May 3, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2017 including:
Total revenues of $45.4 million for the three months ended March 31, 2017. GAAP diluted EPS of $0.04 for the three months ended March 31, 2017. GAAP net income attributable to PDL's shareholders of $7.2 million for the three months ended March 31, 2017. Non-GAAP net income attributable to PDL's shareholders of $13.2 million for the three months ended March 31, 2017. A full... More